LivaNova PLC (LIVN)
55.57
+0.47
(+0.85%)
USD |
NASDAQ |
Apr 26, 16:00
55.57
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.998B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 14.94% |
Valuation | |
PE Ratio | 173.66 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.606 |
Price to Book Value | 2.347 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.4592 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 73.87% |
Profile
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
URL | https://www.livanova.com |
Investor Relations URL | https://investor.livanova.com |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 01, 2024 |
Last Earnings Release | Feb. 21, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
URL | https://www.livanova.com |
Investor Relations URL | https://investor.livanova.com |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 01, 2024 |
Last Earnings Release | Feb. 21, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |